Jump to main content
Jump to site search
Access to RSC content Close the message box

Continue to access RSC content when you are not at your institution. Follow our step-by-step guide.


Issue 1, 2019
Previous Article Next Article

Antibacterial properties and clinical potential of pleuromutilins

Author affiliations

Abstract

Covering: up to 2018

Pleuromutilins are a clinically validated class of antibiotics derived from the fungal diterpene (+)-pleuromutilin (1). Pleuromutilins inhibit bacterial protein synthesis by binding to the peptidyl transferase center (PTC) of the ribosome. In this review we summarize the biosynthesis and recent total syntheses of (+)-pleuromutilin (1). We review the mode of interaction of pleuromutilins with the bacterial ribosome, which involves binding of the C14 extension and the tricyclic core to the P and A sites of the PTC, respectively. We provide an overview of existing clinical agents, and discuss the three primary modes of bacterial resistance (mutations in ribosomal protein L3, Cfr methylation, and efflux). Finally we collect structure–activity relationships from publicly available reports, and close with some forward looking statements regarding future development.

Graphical abstract: Antibacterial properties and clinical potential of pleuromutilins

Back to tab navigation

Article information


Submitted
01 May 2018
First published
06 Jul 2018

Nat. Prod. Rep., 2019,36, 220-247
Article type
Review Article

Antibacterial properties and clinical potential of pleuromutilins

O. Goethe, A. Heuer, X. Ma, Z. Wang and S. B. Herzon, Nat. Prod. Rep., 2019, 36, 220
DOI: 10.1039/C8NP00042E

Social activity

Search articles by author

Spotlight

Advertisements